Insider Buying: Burning Rock Biotech (NASDAQ:BNR) Director Purchases $44,925.00 in Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han bought 5,990 shares of the business’s stock in a transaction on Tuesday, June 23rd. The stock was bought at an average price of $7.50 per share, for a total transaction of $44,925.00. Following the transaction, the director directly owned 18,129,186 shares of the company’s stock, valued at approximately $135,968,895. This represents a 0.03% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han bought 24,900 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $8.00 per share, with a total value of $199,200.00.
• On Wednesday, June 24th, Yusheng Han acquired 250,000 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $8.00 per share, with a total value of $2,000,000.00.
• On Monday, June 22nd, Yusheng Han purchased 104,650 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $7.45 per share, with a total value of $779,642.50.
• On Tuesday, June 16th, Yusheng Han acquired 111,110 shares of Burning Rock Biotech stock. The stock was bought at an average price of $9.00 per share, with a total value of $999,990.00.
• On Friday, June 12th, Yusheng Han acquired 210,000 shares of Burning Rock Biotech stock. The shares were bought at an average price of $9.25 per share, with a total value of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han purchased 24,760 shares of Burning Rock Biotech stock. The shares were purchased at an average price of $8.74 per share, with a total value of $216,402.40.

Burning Rock Biotech Price Performance

BNR stock opened at $9.82 on Friday. Burning Rock Biotech Limited Sponsored ADR has a 12-month low of $3.23 and a 12-month high of $41.72. The company has a quick ratio of 2.81, a current ratio of 3.05 and a debt-to-equity ratio of 0.06. The company’s fifty day simple moving average is $12.35 and its 200 day simple moving average is $19.96. The firm has a market cap of $103.31 million, a price-to-earnings ratio of -11.98 and a beta of 1.32.

Burning Rock Biotech (NASDAQ:BNR) last issued its earnings results on Tuesday, June 9th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.29) by $2.09. The business had revenue of $15.66 million during the quarter, compared to the consensus estimate of $19.21 million. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on BNR shares. Wall Street Zen cut shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Institutional Investors Weigh In On Burning Rock Biotech

Large investors have recently added to or reduced their stakes in the company. Marshall Wace LLP bought a new stake in Burning Rock Biotech in the 4th quarter valued at about $220,000. Renaissance Technologies LLC lifted its stake in shares of Burning Rock Biotech by 13.8% during the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after buying an additional 4,290 shares in the last quarter. Prospera Financial Services Inc boosted its holdings in Burning Rock Biotech by 26.0% in the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after buying an additional 6,430 shares during the period. Finally, Crcm LP boosted its holdings in Burning Rock Biotech by 13.8% in the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after buying an additional 26,809 shares during the period. Hedge funds and other institutional investors own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.